MedTrace Logo

Retrospective Case Study Examining Patient Outcomes Compared to the ChemoFx Assay in Endometrial Cancer Patients

NCT01049126 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 76

Last updated 2011-03-16

No results posted yet for this study

Summary

The purpose of this study is to assess the relationship of assay sensitive patients versus assay resistant patients with progression free survival.

Conditions

Interventions

OTHER

ChemoFx

Chemoresponse Marker Assay

Sponsors & Collaborators

  • Precision Therapeutics

    lead INDUSTRY

Principal Investigators

  • Holly Gallion, MD · Vice President, Clinical Affairs

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-07-31
Primary Completion
2009-10-31
Completion
2010-02-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01049126 on ClinicalTrials.gov